These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 25589482)

  • 41. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Albarrán OG; Ampudia-Blasco FJ
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
    Shehadeh N; Raz I; Nakhleh A
    Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
    [No Abstract]   [Full Text] [Related]  

  • 45. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?
    Swislocki AL; Jialal I
    Metab Syndr Relat Disord; 2016 Feb; 14(1):3-6. PubMed ID: 26677930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
    Sarzani R; Giulietti F; Di Pentima C; Spannella F
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
    Tonneijck L; Muskiet MHA; Blijdorp CJ; Smits MM; Twisk JW; Kramer MHH; Danser AHJ; Diamant M; Joles JA; Hoorn EJ; van Raalte DH
    Am J Physiol Renal Physiol; 2019 Feb; 316(2):F231-F240. PubMed ID: 30353743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.
    Steinberg HO
    Postgrad Med; 2016 May; 128(4):398-408. PubMed ID: 26999348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Papadopoulos C; Kassimis G; Fragakis N; Vassilikos V; Karagiannis A; Doumas M
    Vasc Med; 2022 Oct; 27(5):433-439. PubMed ID: 35754338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
    Baker WL; Buckley LF; Kelly MS; Bucheit JD; Parod ED; Brown R; Carbone S; Abbate A; Dixon DL
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
    Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
    Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus.
    Hinnen D
    J Cardiovasc Nurs; 2013; 28(2):157-65. PubMed ID: 22343215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.